It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
(visit the link for the full news article)
But US consumers will keep paying monopoly prices until 2019
Pfizer's legal monopoly on one of its top-selling drugs just got shredded in Canada. The Canadian Supreme Court has ruled 7-0 the company should have its patent taken away because the drug company attempted to "game" the system, grabbing a patent without disclosing what their invention really was.
Pfizer was able to acquire its Canadian patent without naming the compound required to make Viagra, namely, sildenafil citrate. The Canadian patent system, like all patent systems, is a kind of bargain between patentees, who are given a limited monopoly on a particular product or process, and the public, which is supposed to benefit from the disclosure of a new invention, the justices noted in their opinion.
"Pfizer had the information needed to disclose the useful compound and chose not to release it," the ruling said. "As a matter of policy and sound statutory interpretation, patentees cannot be allowed to 'game' the system in this way."
on appeal from the federal court of appeal
Intellectual property — Patents — Disclosure requirements — Patent for use of compound to treat erectile disfunction — Patent application containing cascading claims ending with two individual compounds — Claims not specifying active compound — Whether patent application meeting disclosure requirements of Patent Act — Whether patent based on sound prediction — Patent Act, R.S.C. 1985, c. P‑4, s. 27(3).
P holds Patent 2,163,446 for the use of a “compound of formula (I)” or a “salt thereof” as a medicament for the treatment of erectile dysfunction (“ED”). The patent’s specification ends with seven cascading claims for successively smaller ranges of compounds, with Claims 6 and 7 relating to a single compound each. Only sildenafil, the subject of Claim 7 and the active compound in Viagra, had been shown to be effective in treating ED at the time of the patent application. Although the patent includes the statement that “one of the especially preferred compounds induces penile erection in impotent males”, the patent application does not disclose that the compound that works is sildenafil, that it is found in Claim 7, or that the remaining compounds had not been found to be effective in treating ED.
T applied for a notice of compliance in order to produce a generic version of Viagra. The Federal Court prohibited the Minister from issuing the requested notice of compliance. The Federal Court of Appeal dismissed the appeal.
Held: The appeal should be allowed. Patent 2,163,446 is void.
In the US, Pfizer's patent rights on Viagra were originally set to expire in 2012. But when generic companies moved to enter the market, Pfizer piled on a "method-of-use" patent over the same drug, set to expire in 2019. A federal judge upheld that patent after a bench trial last year, so Pfizer will be the only company allowed to sell sildenafil in the US for at least seven more years, and prices will remain high.
It appears that the global giant Pfizer (which "owns" more companies of note than you can shake a stick at) has been exposed as one of those mega-corporations who use verbal-legal trickery to secure patents....
Former Monsanto is today known as Pharmacia. Pharmacia is now a wholly owned subsidiary of Pfizer Inc., which together with its subsidiaries operates the Pharmaceuticals Business.
T applied for a notice of compliance in order to produce a generic version of Viagra. The Federal Court prohibited the Minister from issuing the requested notice of compliance. The Federal Court of Appeal dismissed the appeal.
I wonder if this has anything to do with all the generic drug manufacturers in Canada (Apotex et al.) or if it's really just about holding one pharma to account?
... Of course the generics are going to make more money without the patent...